Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
CCXI's Cash-to-Debt is ranked higher than
84% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CCXI' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.43  Med: 720.51 Max: No Debt
Current: No Debt
Equity-to-Asset 0.29
CCXI's Equity-to-Asset is ranked lower than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CCXI: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
CCXI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.78 Max: 0.96
Current: 0.29
0.29
0.96
Interest Coverage No Debt
CCXI's Interest Coverage is ranked higher than
80% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CCXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CCXI' s Interest Coverage Range Over the Past 10 Years
Min: 206.51  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -0.99
Beneish M-Score: 3.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -118.36
CCXI's Operating Margin % is ranked higher than
50% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CCXI: -118.36 )
Ranked among companies with meaningful Operating Margin % only.
CCXI' s Operating Margin % Range Over the Past 10 Years
Min: -731.32  Med: -179.14 Max: 31.55
Current: -118.36
-731.32
31.55
Net Margin % -113.94
CCXI's Net Margin % is ranked lower than
51% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CCXI: -113.94 )
Ranked among companies with meaningful Net Margin % only.
CCXI' s Net Margin % Range Over the Past 10 Years
Min: -736.13  Med: -174.71 Max: 31.41
Current: -113.94
-736.13
31.41
ROE % -59.70
CCXI's ROE % is ranked lower than
61% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CCXI: -59.70 )
Ranked among companies with meaningful ROE % only.
CCXI' s ROE % Range Over the Past 10 Years
Min: -65.3  Med: -33.61 Max: 20.21
Current: -59.7
-65.3
20.21
ROA % -20.68
CCXI's ROA % is ranked higher than
59% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CCXI: -20.68 )
Ranked among companies with meaningful ROA % only.
CCXI' s ROA % Range Over the Past 10 Years
Min: -48.48  Med: -31.15 Max: 15.1
Current: -20.68
-48.48
15.1
ROC (Joel Greenblatt) % -3349.39
CCXI's ROC (Joel Greenblatt) % is ranked lower than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CCXI: -3349.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CCXI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4386.18  Med: -2689.25 Max: 66.57
Current: -3349.39
-4386.18
66.57
3-Year Revenue Growth Rate 20.20
CCXI's 3-Year Revenue Growth Rate is ranked higher than
73% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CCXI: 20.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CCXI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 20.2
Current: 20.2
0
20.2
3-Year EBITDA Growth Rate -2.80
CCXI's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CCXI: -2.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CCXI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -0.6 Max: 129.2
Current: -2.8
0
129.2
3-Year EPS without NRI Growth Rate -3.30
CCXI's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CCXI: -3.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CCXI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.3 Max: 105.2
Current: -3.3
0
105.2
GuruFocus has detected 2 Warning Signs with ChemoCentryx Inc CCXI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CCXI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CCXI Guru Trades in Q3 2016

Jim Simons 197,981 sh (+184.12%)
» More
Q4 2016

CCXI Guru Trades in Q4 2016

Jim Simons 470,581 sh (+137.69%)
» More
Q1 2017

CCXI Guru Trades in Q1 2017

Jim Simons 616,581 sh (+31.03%)
» More
Q2 2017

CCXI Guru Trades in Q2 2017

Jim Simons 723,151 sh (+17.28%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:NAS:MRUS, NAS:CLDX, NAS:SYRS, XTER:FYB, NAS:ABUS, ASX:SPL, NAS:CBAY, NAS:GERN, ROCO:6471, HKSE:01061, NAS:CRBP, XKRX:083790, WAR:MAB, LSE:OXB, NAS:CRVS, NAS:NVAX, XKRX:084110, XKRX:031390, NAS:CNCE, XSWX:SKIN » details
Traded in other countries:2CX.Germany,
Headquarter Location:USA
ChemoCentryx Inc is a biopharmaceutical company. It is engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Chemocentryx is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are: antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Top Ranked Articles about ChemoCentryx Inc

ChemoCentryx to Present at Three Upcoming Investor Conferences
ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017
Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS)
ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
ChemoCentryx Reports First Quarter 2017 Financial Results
ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017
ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)

MOUNTAIN VIEW, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for avacopan in the treatment of patients with C3 glomerulopathy (C3G).
C3G is a severe kidney disease characterized by deposits of proteins from the body’s complement system into and around the kidney’s filtration units, the glomeruli. The deposition of complement protein disrupts kidney function and also triggers a profoundly destructive inflammation of the kidney. The disease process ultimately leads to renal failure, with the need for dialysis and kidney transplant. There is currently no approved treatment for C3G, and relapse is common even after kidney transplant.  Avacopan targets the complement C5a receptor (C5aR) which drives the destructive inflammatory cells in C3G and other kidney diseases.  In this way, avacopan is designed to arrest the ongoing process of kidney damage in C3G, allowing kidney function to stabilize. “Scientific and clinical evidence supports avacopan’s potential in the treatment of C3G, a debilitating kidney disorder that strikes young people,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. â€œReceipt of FDA orphan status will allow us to expedite development of this promising treatment option for C3G, which has already had a life-changing effect on a C3G patient treated continuously with avacopan for well over a year under the Special Needs program (the equivalent of a compassionate use protocol) in the United Kingdom.” ChemoCentryx plans to initiate a multi-center clinical endpoint study of avacopan for the treatment of C3G in the first half of 2017. About Avacopan (CCX168) Avacopan (CCX168) is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.  Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while successfully allowing elimination of high-dose steroids, part of the standard of care for AAV patients. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has now granted avacopan orphan-drug designation for all three of these diseases: AAV, C3G and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis). Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need. About Complement 3 Glomerulopathy (C3G) C3 glomerulopathy is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. Patients with C3G often have high levels of protein in the urine (proteinuria) and experience progressive deterioration in renal function. Without treatment, C3G leads to kidney failure, with kidney transplant often the only option.  Even after transplantation, the new kidney will frequently manifest the disease. There is no approved treatment for C3G; non-specific immunosuppressants are frequently employed. The estimated prevalence of C3G is two-to-three per million people. About ChemoCentryx ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases, and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare kidney diseases, avacopan (CCX168) and CCX140. Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.  Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has now granted avacopan orphan-drug designation for three indications, AAV, C3G and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis).  Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need. The Company’s other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. ChemoCentryx’s Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China. ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other Inflammatory and autoimmune diseases and in cancer. Forward-Looking Statements
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements whether avacopan (CCX168) will be shown to be safe and effective in the treatment of C3 glomerulopathy and other rare diseases and the Company’s statement regarding the timing of initiating additional clinical trials to further investigate avacopan in the treatment of C3G. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 14, 2017 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Contacts:

Susan M. Kanaya
Executive Vice President
Chief Financial and Administrative Officer
[email protected]

Media:
Denise Powell
[email protected]
510.703.9491

Investors:
Steve Klass, Burns McClellan
212.213.0006
[email protected]

Read more...
ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results

-- Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales --
-- Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced financial results for the fourth quarter and full year ended December 31, 2016. “2016 was a transformative year for ChemoCentryx,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We are now entering the next step in our evolution, driving the registration trials of our novel drug candidates and preparing for their commercialization.  We have established a strong financial position through our partnership with Vifor Pharma and are now well positioned to execute on our plan to create value for patients and shareholders, starting with kidney disease.” Recent Highlights In December 2016, ChemoCentryx launched the Phase III ADVOCATE trial with avacopan for the treatment of ANCA-associated Vasculitis (AAV), a devastating autoimmune disease that destroys blood vessels and can lead to kidney failure. The design of the trial was agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). ADVOCATE is a randomized, double-blind two arm study enrolling 300 patients across 200 sites in the United States and Europe.In December 2016, ChemoCentryx and Vifor Pharma announced an expansion of their global kidney health alliance to include CCX140.  Together with the avacopan deal announced in May 2016, the partnership with Vifor Pharma brought a total of $135 million in upfront cash commitments to ChemoCentryx in 2016, with the prospect of a further $1.2 billion in potential milestone payments. In February 2017, ChemoCentryx and Vifor Pharma announced that they had harmonized the geographic commercialization rights for both drug candidates, with a further $20 million upfront commitment to ChemoCentryx.  ChemoCentryx retains the rights to commercialize avacopan and CCX140 for orphan and rare renal diseases in the United States and China, and will receive tiered double digit royalties on Vifor Pharma’s net sales in other markets. Fourth Quarter and Full Year 2016 Financial Results Pro forma cash, cash equivalents and investments totaled $194 million at December 31, 2016, which included the $50.0 million upfront commitment in connection with the December 2016 CCX140 agreement and the $20.0 million upfront commitment related to the February 2017 amendment to the avacopan agreement. Revenue was $4.9 million for the fourth quarter, compared to zero for the same period in 2015.  For the full year ended December 31, 2016, revenue was $11.9 million, compared to zero for 2015. The increase in revenue from 2015 to 2016 was due to: (i) amortization of the upfront payment from Vifor Pharma pursuant to the avacopan agreement and (ii) grant revenue from the FDA to support the clinical development of avacopan for the treatment of patients with AAV. Research and development (R&D) expenses were $9.3 million for the fourth quarter, compared to $8.2 million for the same period in 2015. Full year 2016 R&D expenses were $38.0 million compared to $33.2 million in 2015. The increase in R&D expenses from 2015 to 2016 was primarily attributable to higher expenses associated with avacopan for start-up activities and ancillary studies related to the Phase III development program in patients with AAV. This increase was partially offset by lower expenses associated with Phase II development of avacopan, due to the completion of the CLEAR and CLASSIC Phase II clinical trials in 2016. General and administrative (G&A) expenses were $3.6 million for the fourth quarter, compared to $3.4 million for the same period in 2015. Full year 2016 G&A expenses were $14.7 million, compared to $14.5 million in 2015. The increase from 2015 to 2016 was primarily due to higher professional service fees relating to the Company’s business development efforts. Net losses for the fourth quarter were $7.7 million, compared to $11.6 million for the same period in 2015.  Full year 2016 net losses, at $40.0 million, were also lower than the $47.3 million net losses in 2015.  Total shares outstanding at December 31, 2016 were approximately 48.1 million shares. The Company expects to utilize cash and cash equivalents between $50 million and $55 million in 2017. Conference Call and Webcast The Company will host a conference call and webcast today, March 14, 2017 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 80376833. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the conference call. About ChemoCentryx ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases, and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare kidney diseases, avacopan (CCX168) and CCX140. Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.  Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has now granted avacopan orphan-drug designation for AAV and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis).  Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need. The Company’s other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. ChemoCentryx’s Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China.  ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other Inflammatory and autoimmune diseases and in cancer.  Forward-Looking Statements
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the achievement of anticipated goals and milestones, whether the Company's alliance with Vifor Pharma will provide milestone payments and royalties on international sales and whether the Company’s drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 14, 2017 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Source: ChemoCentryx, Inc. CCXI-G ChemoCentryx, Inc.
 Consolidated Statement of Operations Data
 (in thousands, except per share data)
                   Three Months Ended   Twelve Months Ended       December 31,    December 31,          2016     2015     2016     2015   Consolidated Statement of Operations Data:                         Revenue:            Collaboration and license revenue   $4,684  $-  $11,435  $-  Grant revenue    205   -   500   -  Total revenue    4,889   -   11,935   -               Operating expenses:           Research and development    9,249   8,230   37,945   33,183  General and administrative    3,556   3,430   14,710   14,506  Total operating expenses    12,805   11,660   52,655   47,689  Loss from operations    (7,916)  (11,660)  (40,720)  (47,689)              Interest income     251   86   757   384  Net loss    $(7,665) $(11,574) $(39,963) $(47,305)              Basic and diluted net loss per share   $(0.16) $(0.26) $(0.86) $(1.08)              Shares used to compute basic and diluted net
  loss per share    47,900   44,145   46,432   43,890                                                   December 31,              2016     2015                          (in thousands)  Consolidated Balance Sheet Data            Cash, cash equivalents and investments       $123,761  $76,289  Accounts receivable (1)        30,205   -  Working capital         110,356   66,541  Total assets         155,872   78,155  Accumulated deficit        (307,059)  (267,096) Total stockholders’ equity        49,889   72,507                            (1) Accounts receivable excludes the additional $20 million cash commitment due from Vifor in December 2017 in connection with the CCX140agreement as well as the $20 million cash commitment from Vifor in connection with the February 2017 Avacopan territory expansion agreement.   

Contacts:

Susan M. Kanaya                                                          
Executive Vice President,                                                           
Chief Financial and Administrative Officer            
[email protected]                                          

Media:
Denise Powell
[email protected]
510.703.9491

Investors:
Steve Klass, Burns McClellan
212.213.0006                
[email protected]

Read more...
ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017

MOUNTAIN VIEW, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to discuss these results and to answer questions.
To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 80376833. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call. About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases, and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare kidney diseases, avacopan (CCX168) and CCX140. Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.  Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for AAV, and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis).  Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need. The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China. ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Source: ChemoCentryx, Inc.
Contacts:
Susan M. Kanaya
Senior Vice President, Finance and Chief Financial Officer
[email protected]

Media:
Denise Powell
[email protected]
510.703.9491

Investors:
Steve Klass
Burns McClellan
212.213.0006
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.07
CCXI's PB Ratio is ranked lower than
78% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CCXI: 8.07 )
Ranked among companies with meaningful PB Ratio only.
CCXI' s PB Ratio Range Over the Past 10 Years
Min: 0.74  Med: 3.07 Max: 12.46
Current: 8.07
0.74
12.46
PS Ratio 12.37
CCXI's PS Ratio is ranked lower than
54% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CCXI: 12.37 )
Ranked among companies with meaningful PS Ratio only.
CCXI' s PS Ratio Range Over the Past 10 Years
Min: 11.76  Med: 70.48 Max: 550
Current: 12.37
11.76
550
EV-to-EBIT -6.85
CCXI's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CCXI: -6.85 )
Ranked among companies with meaningful EV-to-EBIT only.
CCXI' s EV-to-EBIT Range Over the Past 10 Years
Min: -75.6  Med: -5.6 Max: -0.1
Current: -6.85
-75.6
-0.1
EV-to-EBITDA -6.96
CCXI's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CCXI: -6.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
CCXI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -86  Med: -5.7 Max: -0.1
Current: -6.96
-86
-0.1
EV-to-Revenue 7.93
CCXI's EV-to-Revenue is ranked higher than
59% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CCXI: 7.93 )
Ranked among companies with meaningful EV-to-Revenue only.
CCXI' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.8  Med: 33.7 Max: 441.3
Current: 7.93
3.8
441.3
Current Ratio 2.78
CCXI's Current Ratio is ranked lower than
64% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CCXI: 2.78 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 2.78  Med: 9.76 Max: 19.54
Current: 2.78
2.78
19.54
Quick Ratio 2.78
CCXI's Quick Ratio is ranked lower than
61% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CCXI: 2.78 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 2.78  Med: 9.76 Max: 19.54
Current: 2.78
2.78
19.54
Days Sales Outstanding 3.02
CCXI's Days Sales Outstanding is ranked higher than
94% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CCXI: 3.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.02  Med: 104.12 Max: 923.74
Current: 3.02
3.02
923.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
CCXI's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CCXI: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15  Med: -6.7 Max: 0
Current: -3.9
-15
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.07
CCXI's Price-to-Net-Cash is ranked lower than
74% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CCXI: 15.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CCXI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.95  Med: 4.58 Max: 29.6
Current: 15.07
1.95
29.6
Price-to-Net-Current-Asset-Value 13.29
CCXI's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CCXI: 13.29 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CCXI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.92  Med: 4.52 Max: 25.1
Current: 13.29
1.92
25.1
Price-to-Tangible-Book 8.07
CCXI's Price-to-Tangible-Book is ranked lower than
70% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CCXI: 8.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CCXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.56  Med: 3.59 Max: 11.12
Current: 8.07
1.56
11.12
Price-to-Median-PS-Value 0.18
CCXI's Price-to-Median-PS-Value is ranked higher than
93% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CCXI: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CCXI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.56 Max: 3.75
Current: 0.18
0.17
3.75
Earnings Yield (Greenblatt) % -14.57
CCXI's Earnings Yield (Greenblatt) % is ranked lower than
61% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CCXI: -14.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CCXI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1626.7  Med: -17.8 Max: -1.3
Current: -14.57
-1626.7
-1.3

More Statistics

Revenue (TTM) (Mil) $26.31
EPS (TTM) $ -0.62
Beta1.81
Short Percentage of Float7.80%
52-Week Range $5.52 - 10.80
Shares Outstanding (Mil)48.71

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}